BPC 157 for Acute Hamstring Muscle Strain Repair

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Hamstring Muscle Strain, Skeletal Muscle Injury

In brief

This randomized, double-blind, placebo-controlled Phase 2 study evaluates whether pentadecapeptide BPC 157 (BPC-157), an investigational peptide, can speed structural healing and functional recovery after an acute grade II hamstring muscle strain. Participants will receive BPC 157 or placebo for 14 days in addition to a standardized rehabilitation program. The co-primary endpoints are time to return to unrestricted sport and change in MRI-assessed injury volume at Day 14.

Key facts

Study ID

NCT07437547

Run by

Hudson Biotech

People needed

120

Starts

2026-02-02

Expected to finish

2028-02-17

Last updated by the study team

2026-02-27

Who can join

Age: 18 and older, up to 45. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 to 45 years.
• Acute posterior thigh pain consistent with hamstring strain with onset within 72 hours prior to screening.
• MRI-confirmed grade II hamstring strain of the biceps femoris, semitendinosus, or semimembranosus, with measurable lesion.
• Pre-injury physical activity >= 3 sessions/week or participation in organized recreational sport.
• Willingness to follow the standardized rehabilitation protocol and attend all study visits.
• For participants of childbearing potential: negative pregnancy test at baseline and agreement to use effective contraception during dosing and for 30 days after last dose.

You may not qualify if…

• Grade III hamstring tear, tendon avulsion, or injury requiring surgical management.
• Concomitant lower extremity injury that would interfere with rehabilitation or outcome assessment.
• Prior hamstring strain on the index limb within the past 6 months.
• Use of systemic corticosteroids, anabolic agents, platelet-rich plasma, stem-cell products, or investigational peptides/growth factors within 30 days prior to screening.
• Known bleeding disorder or current therapeutic anticoagulation.
• Significant uncontrolled medical illness (e.g., severe cardiovascular, hepatic, or renal disease) that increases study risk.
• Known allergy or hypersensitivity to components of the investigational product or placebo.
• Pregnant or breastfeeding.
• Current participation in another interventional clinical study or participation within 30 days prior to screening.
• Currently subject to a formal anti-doping testing program (e.g., WADA/USADA-aligned) where use of an investigational peptide could create a regulatory conflict, unless explicitly approved by the relevant authority

Where it is running

• Peking University Shenzhen Hospital — Shenzhen, Guangdong, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.